U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07230652) titled 'A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020' on Aug. 06.
Brief Summary: This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable schizophrenia.
Study Start Date: Aug. 20
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Alzheimer's Disease Psychosis
Intervention:
DRUG: LY03020
administered orally
DRUG: Placebo
administered orally
Recruitment Status: RECRUITING
Sponsor: Luye Pharma Group Ltd.
Published by HT Digital Content Services...